Press release
January 11, 2026
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
Krystal Biotech, Inc. (KRYS)
Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to $107 million Robust clinical pipeline with multibillion dollar opportunities and strong balance sheet for sustained growth PITTSBURGH , Jan. 11, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced